Study Evaluating Efficacy and Safety of Crisaborole in Adults With Stasis Dermatitis
Condition: Stasis Dermatitis Interventions: Drug: crisaborole ointment; Other: vehicle ointment Sponsor: Pfizer Not yet recruiting
ConclusionsEvidence on the efficacy and safety of drugs targeting the JAK/STAT pathway for the treatment of patients with AD, vitiligo, or AA is increasing but is still of low quality.
Authors: Maloney NJ, Tegtmeyer K, Zhao J, Worswick S Abstract Dupilumab inhibits the interleukin-4 receptor subunit α and is FDA approved for treatment of moderate-to-severe atopic dermatitis. It is a relatively new drug, and whether it is efficacious for other diseases in dermatology is an area of increasing interest. We searched the literature and ClinicalTrials.gov database for uses of dupilumab beyond atopic dermatitis in dermatology and for ongoing studies on new uses for dupilumab. Off-label reports identified described use of dupilumab for several different dermatologic conditions, including allergic c...
Authors: Sheriff T, Lin MJ, Dubin D, Khorasani H Abstract Cannabis is increasingly being used world-wide to treat a variety of dermatological conditions. Medicinal cannabis is currently legalized in Canada, 31 states in America and 19 countries in Europe. The authors reviewed the literature on the pharmacology and use of cannabinoids in treating a variety of skin conditions including acne, atopic dermatitis, psoriasis, skin cancer, pruritus, and pain. Cannabinoids have demonstrated anti-inflammatory, antipruritic, anti-ageing, and antimalignancy properties by various mechanisms including interacting with the newly ...
Flea bite is considered to be the main cause of allergic dermatitis in cats. There is a need for treatments able to control clinical signs of allergic dermatitis associated with flea bite in cats.
ConclusionsThe present study allowed the identification of different protein areas specific to these studied groups. The protein spots of interest were identified by UHPLC-MS/MS. It has been possible to establish a link between a specific symptomatology and the newly identified responsible allergens.
Chandra Sekhar Sirka, Kananbala Sahu, Swetalina Pradhan, Arpita Nibedita RoutIndian Journal of Dermatology, Venereology, and Leprology 2019 85(6):623-626
PMID: 31603528 [PubMed - as supplied by publisher]
Conclusions. Hypozincemia is rather prevalent in AD, and severe AD and high IgE increase its risk. An adjunct oral zinc may help reducing severe poorly responsive AD. PMID: 31594297 [PubMed - as supplied by publisher]
Treatment for children with moderate-severe atopic dermatitis is a significant unmet need; dupilumab is currently licensed only for patients over age 11.Off-label access to dupilumab is achievable, and shows similar treatment success rates and tolerability as in adult patients, but optimal pediatric dosing has not been defined..
Applying strips of tape to collect skin samples for biomarker testing may be a viable alternative to biopsy for serial evaluation of early-onset atopic dermatitis in children.Medscape Medical News